Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ABO-206
- Development stage
- Preclinical
- Lead developer
- Arbor Biotechnologies
- Modality
- CRISPR-Cas9 → CRISPR Systems → Programmable Nucleases → Gene Editing → Gene Therapies
- Administration
- Intrathecal
01
Overview
ABO-206 is a preclinical gene-editing candidate developed by Arbor Biotechnologies for the treatment of an undisclosed central nervous system (CNS) disorder. The therapy utilizes Arbor's proprietary Compact RT Editing technology, a form of reverse transcriptase-mediated gene editing designed for high precision and a compact size that facilitates delivery via a single adeno-associated virus (AAV) vector. By leveraging a diverse library of CRISPR-based editors, the program aims to address neurological conditions that require precise genomic modifications. As of 2024, ABO-206 is in the discovery phase of development.
02
Targets
DNA
Beyond the preview
Go deeper on ABO-206.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ABO-206.